Core Viewpoint - Water Sheep Co., Ltd. has experienced fluctuations in stock price and trading volume, with a notable increase in revenue and profit year-on-year, indicating potential growth in the cosmetics sector [1][2]. Company Performance - As of December 2, Water Sheep's stock price was 19.93 yuan per share, down 2.02%, with a total market capitalization of 7.773 billion yuan [1]. - The company has seen a 50.76% increase in stock price year-to-date, with a 3.00% rise in the last five trading days, but a decline of 1.48% over the last 20 days and 11.34% over the last 60 days [1]. - For the period from January to September 2025, Water Sheep achieved a revenue of 3.409 billion yuan, representing a year-on-year growth of 11.96%, and a net profit of 136 million yuan, up 44.01% year-on-year [2]. Shareholder and Institutional Holdings - As of November 10, the number of shareholders increased to 30,000, a rise of 10.64%, while the average circulating shares per person decreased by 9.61% to 11,966 shares [2]. - The company has distributed a total of 142 million yuan in dividends since its A-share listing, with 77.8142 million yuan distributed over the past three years [3]. - Notable institutional shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 5.6594 million shares, and new entrants such as Huaxia Domestic Demand Driven Mixed A and Caitong Asset Management [3]. Business Overview - Water Sheep Co., Ltd. specializes in the research, production, and sales of cosmetics, with its main revenue sources being lotions and creams (81.84%), masks (17.32%), and other products (0.84%) [1]. - The company operates within the beauty care sector, specifically in branded cosmetics, and is associated with concepts such as DeepSeek, new retail, and Xiaomi [2].

11月28日，华熙生物盘中下跌2.01%，截至09:54，报46.79元/股，成交5361.81万元，换手率0.24%，总 市值225.38亿元。 资金流向方面，主力资金净流出220.33万元，特大单买入216.98万元，占比4.05%，卖出397.92万元，占 比7.42%；大单买入943.10万元，占比17.59%，卖出982.50万元，占比18.32%。 华熙生物今年以来股价跌8.13%，近5个交易日跌4.26%，近20日跌13.34%，近60日跌19.02%。 资料显示，华熙生物科技股份有限公司位于山东省济南市高新技术开发区天辰大街678号，成立日期 2000年1月3日，上市日期2019年11月6日，公司主营业务涉及微生物发酵和交联两大技术平台,开发有助 于人类生命健康的生物活性材料,建立了从原料到医疗终端产品、功能性护肤品及功能性食品的全产业 链业务体系,服务于全球的医药、化妆品、食品制造企业、医疗机构及终端用户。主营业务收入构成 为：皮肤科学创新转化业务40.34%，医疗终端产品29.76%，原料产品27.70%，其他2.17%，其他(补 充)0.03%。 截至11月20日，华熙生物股东户数3.0 ...

Core Viewpoint - Marubi Biotechnology's stock has shown fluctuations in recent trading sessions, with a year-to-date increase of 8.63% and a recent decline over the past 60 days of 15.88% [1][2]. Company Overview - Marubi Biotechnology Co., Ltd. was established on April 2, 2002, and went public on July 25, 2019. The company is located in Guangzhou and specializes in the research, design, production, sales, and service of various skincare products [1]. - The revenue composition of Marubi includes skincare products (39.05%), beauty and other products (29.37%), eye care products (23.81%), cleansing products (7.67%), and other businesses (0.10%) [1]. Financial Performance - For the period from January to September 2025, Marubi achieved a revenue of 2.45 billion yuan, representing a year-on-year growth of 25.51%. The net profit attributable to the parent company was 244 million yuan, with a growth of 2.13% [2]. - Since its A-share listing, Marubi has distributed a total of 1.08 billion yuan in dividends, with 710 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Marubi was 18,900, an increase of 8.86% from the previous period. The average number of circulating shares per person was 21,205, a decrease of 8.14% [2]. - Among the top ten circulating shareholders, several funds from the Fortune series hold significant stakes, with the largest being Fortune Consumption Theme Mixed A, holding 3.69 million shares [3].

Core Viewpoint - Huaxi Biological experienced a decline in stock price, with a year-to-date drop of 4.52% and a significant decrease in revenue and net profit for the first nine months of 2025 compared to the previous year [1][2]. Company Overview - Huaxi Biological Technology Co., Ltd. was established on January 3, 2000, and went public on November 6, 2019. The company is located in Jinan, Shandong Province, and focuses on microbial fermentation and cross-linking technology platforms to develop bioactive materials for health [1]. - The company has a full industry chain business model that includes raw materials, medical terminal products, functional skincare products, and functional foods, serving global pharmaceutical, cosmetic, food manufacturing companies, medical institutions, and end-users [1]. Financial Performance - For the period from January to September 2025, Huaxi Biological reported operating revenue of 3.163 billion yuan, a year-on-year decrease of 18.36%, and a net profit attributable to shareholders of 252 million yuan, down 30.29% year-on-year [2]. - The company has distributed a total of 1.138 billion yuan in dividends since its A-share listing, with 528 million yuan distributed over the past three years [3]. Shareholder Information - As of November 20, 2025, Huaxi Biological had 30,100 shareholders, a decrease of 0.62% from the previous period, with an average of 16,014 circulating shares per shareholder, which increased by 0.62% [2]. - Major shareholders include various ETFs, with significant reductions in holdings noted for several funds, indicating a potential shift in institutional investment [3].

Core Viewpoint - Water Goat Co., Ltd. has shown a significant increase in stock price this year, but recent trading indicates a decline in the short term, raising questions about future performance and investor sentiment [1][2]. Financial Performance - For the period from January to September 2025, Water Goat achieved a revenue of 3.409 billion yuan, representing a year-on-year growth of 11.96%. The net profit attributable to shareholders was 136 million yuan, reflecting a substantial increase of 44.01% compared to the previous year [2]. - The company has distributed a total of 142 million yuan in dividends since its A-share listing, with 77.8142 million yuan distributed over the past three years [3]. Stock Market Activity - As of November 25, Water Goat's stock price rose by 2.09% to 19.50 yuan per share, with a trading volume of 174 million yuan and a turnover rate of 2.50%, resulting in a total market capitalization of 7.605 billion yuan [1]. - The stock has increased by 47.50% year-to-date, but has seen a decline of 9.89% over the last five trading days, 11.84% over the last 20 days, and 9.60% over the last 60 days [1]. Shareholder Structure - As of November 10, the number of shareholders for Water Goat increased to 30,000, a rise of 10.64%. The average number of circulating shares per shareholder decreased by 9.61% to 11,966 shares [2]. - Notable changes in institutional holdings include Hong Kong Central Clearing Limited becoming the sixth largest shareholder with 8.1833 million shares, an increase of 5.6594 million shares from the previous period. New shareholders include Huaxia Domestic Demand Driven Mixed A and Caitong Asset Management [3]. Business Overview - Water Goat Co., Ltd. is based in Changsha, Hunan Province, and was established on November 1, 2012. It was listed on February 8, 2018. The company's main business involves the research, production, and sales of cosmetics, with the primary revenue sources being lotions and creams (81.84%), masks (17.32%), and other products (0.84%) [1][2].

Core Viewpoint - Marubi Biotechnology's stock has shown fluctuations in recent trading, with a current price of 33.64 CNY per share and a market capitalization of 13.49 billion CNY, reflecting a year-to-date increase of 6.76% [1] Financial Performance - For the period from January to September 2025, Marubi Biotechnology achieved a revenue of 2.45 billion CNY, representing a year-on-year growth of 25.51%, while the net profit attributable to shareholders was 244 million CNY, up 2.13% year-on-year [2] - Cumulative cash dividends since the company's A-share listing amount to 1.08 billion CNY, with 710 million CNY distributed over the past three years [3] Stock Market Activity - As of November 25, 2023, Marubi's stock price increased by 2.25% during the trading session, with a trading volume of approximately 79.75 million CNY and a turnover rate of 0.60% [1] - The stock has appeared on the "Dragon and Tiger List" once this year, with the most recent occurrence on August 25, 2023, where it recorded a net buy of -779.08 million CNY [1] Shareholder Information - As of September 30, 2025, the number of shareholders increased by 8.86% to 18,900, with an average of 21,205 circulating shares per shareholder, a decrease of 8.14% [2] - Among the top ten circulating shareholders, several funds maintained their holdings, while Hong Kong Central Clearing Limited exited the list [3]

11月24日，华熙生物盘中上涨2.03%，截至13:15，报49.86元/股，成交6169.62万元，换手率0.26%，总 市值240.16亿元。 资金流向方面，主力资金净流出106.80万元，大单买入810.65万元，占比13.14%，卖出917.46万元，占 比14.87%。 截至10月31日，华熙生物股东户数3.06万，较上期增加0.86%；人均流通股15749股，较上期减少 0.85%。2025年1月-9月，华熙生物实现营业收入31.63亿元，同比减少18.36%；归母净利润2.52亿元，同 比减少30.29%。 分红方面，华熙生物A股上市后累计派现11.38亿元。近三年，累计派现5.28亿元。 机构持仓方面，截止2025年9月30日，华熙生物十大流通股东中，易方达上证科创板50ETF（588080） 位居第三大流通股东，持股696.42万股，相比上期减少101.36万股。华夏上证科创板50成份ETF （588000）位居第四大流通股东，持股681.95万股，相比上期减少382.34万股。华宝中证医疗ETF （512170）位居第七大流通股东，持股537.40万股，相比上期减少105.90万股。南方中 ...

Core Viewpoint - The stock of Jia Bi You experienced a decline of 2.04% on November 21, with a current price of 23.04 CNY per share, reflecting a significant drop in recent trading days [1] Company Overview - Jia Bi You Biotechnology (Wuhan) Co., Ltd. was established on September 22, 2004, and went public on December 19, 2019. The company specializes in the research, production, and sales of polyunsaturated fatty acids such as ARA and DHA, as well as natural β-carotene, with applications in infant formula, dietary supplements, and special medical foods [2] - The revenue composition of Jia Bi You includes ARA products at 76.16%, DHA products at 21.24%, and other supplements at 2.60% [2] - The company is classified under the basic chemical industry, specifically in chemical products related to food and feed additives, and is associated with concepts such as pet economy, synthetic biology, cosmetics, multiple births, and Hubei Free Trade Zone [2] Financial Performance - For the period from January to September 2025, Jia Bi You achieved a revenue of 428 million CNY, representing a year-on-year growth of 10.56%. The net profit attributable to the parent company was 129 million CNY, showing a significant increase of 54.18% [2] - Since its A-share listing, Jia Bi You has distributed a total of 243 million CNY in dividends, with 103 million CNY distributed over the past three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders for Jia Bi You was 8,362, an increase of 1.01% from the previous period, while the average circulating shares per person decreased by 1.00% to 20,127 shares [2] - Notably, several institutional investors, including 华夏稳增混合 and 鹏华优质治理混合(LOF)A, have exited the list of the top ten circulating shareholders [3]

Core Viewpoint - The stock of Furuida has experienced a decline, with a current price of 7.75 yuan per share and a market capitalization of 7.878 billion yuan, reflecting a challenging financial performance in recent periods [1][2]. Company Performance - Furuida's stock price has increased by 3.33% year-to-date, but it has seen a decline of 3.00% over the last five trading days, 1.77% over the last 20 days, and 9.57% over the last 60 days [1]. - For the period from January to September 2025, Furuida reported a revenue of 2.597 billion yuan, a year-on-year decrease of 7.34%, and a net profit attributable to shareholders of 142 million yuan, down 17.19% year-on-year [2]. Shareholder and Market Activity - As of September 30, 2025, Furuida had 44,500 shareholders, a decrease of 6.27% from the previous period, with an average of 22,827 circulating shares per shareholder, an increase of 6.69% [2]. - The company has made cumulative cash distributions of 1.196 billion yuan since its A-share listing, with 213 million yuan distributed over the last three years [3]. Institutional Holdings - Among the top ten circulating shareholders, the Southern CSI 1000 ETF holds 4.6498 million shares, having decreased its holdings by 70,900 shares compared to the previous period [3].

Core Viewpoint - Shanghai Jahwa's stock price has experienced fluctuations, with a year-to-date increase of 39.41% but a recent decline in the last five and twenty trading days [1][2]. Group 1: Stock Performance - As of November 20, Shanghai Jahwa's stock price was 23.52 CNY per share, with a market capitalization of 15.81 billion CNY [1]. - The stock has seen a net outflow of 5.51 million CNY in principal funds, with large orders accounting for 8.90% of total buying and 19.60% of total selling [1]. - Year-to-date, the stock has risen by 39.41%, but it has dropped by 4.39% in the last five trading days and 11.74% in the last twenty trading days [1]. Group 2: Financial Performance - For the period from January to September 2025, Shanghai Jahwa reported a revenue of 4.96 billion CNY, representing a year-on-year growth of 10.83%, and a net profit attributable to shareholders of 405 million CNY, which is a 149.12% increase year-on-year [2]. - The company has cumulatively distributed 3.595 billion CNY in dividends since its A-share listing, with 344 million CNY distributed in the last three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Shanghai Jahwa was 29,600, a decrease of 21.58% from the previous period, while the average circulating shares per person increased by 27.52% to 22,704 shares [2]. - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 36.55 million shares, an increase of 3.77 million shares from the previous period [3].